BIOXCEL THERAPEUTICS INC

BioXcel insider buys signal optimism as NeuroShield nears FDA review – promising new GBM therapy with strong efficacy, low toxicity and potential market upside.

CEO buys 18k shares as Bioxcel’s Phase II data release approaches, signaling confidence in its AI‑driven neuroscience pipeline and potential upside.

BioXcel’s insider buying, clinical progress in Alzheimer’s and cancer trials, and upcoming regulatory milestones signal potential upside for investors.

Insider buying of Bioxcel Therapeutics stock signals confidence amid AI‑driven drug discovery and upcoming FDA IND filings for neuro‑inflammatory therapies. Click to learn how Javier’s trades and clinical milestones may boost value.